VISTA-GROUP
10.4.2018 18:52:03 CEST | Business Wire | Press release
Vista Entertainment Solutions (Vista Cinema), the leading provider of cinema management software for the global cinema exhibition market, has completed the rollout for its first customer in Italy, The Space Cinema, which operates 36 cinemas with 362 screens. The Space Cinema is part of Vue International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006322/en/
Vista Group Chief Executive Kimbal Riley describes the rollout as a fantastic achievement. “This was a challenging regulatory process in a new territory for Vista and builds on the strong relationship we have with Vue International. It’s a great testament to our excellent local partners that we’ve been able to complete this rollout.”
Managing Director, Europe, Middle East and Africa at Vista Entertainment Solutions, Mischa Kay says: “Together with the fantastic team at The Space Cinema, we have successfully rolled out a broad selection of the Vista Cinema software suite across the Italian circuit. Italy is a top 20 cinema-going market and represents a significant opportunity not only for Vista Cinema, but for the Vista Group as a whole, to provide business benefits to the Italian industry.”
“Vue International continues to implement best practices across its group of circuits in Europe,” says Roland Jones, Executive Director, Technical Services, Vue International. “We are pleased to have extended our relationship with Vista, with whom we have worked extensively in the UK for many years. By introducing Vista’s state-of-the-art, integrated operating system to cinemas such as The Space, we maximize a host of benefits that only the leading global cinema system can deliver.”
The Managing Director of The Space Cinema, Toby Bradon, has also welcomed the completion of the rollout: “On behalf of The Space Cinema, we are very pleased to be the first Italian circuit working with Vista. Following a rapid and successful implementation we look forward to maximising the benefits of Vista’s modern, class-leading cinema operating system. Working in conjunction with our colleagues at Vue International, The Space Cinema continues to invest in its customer experience supporting our mission to be the first choice in cinema entertainment in Italy.”
About The Space Cinema:
The Space Cinema is a leading cinema operator in Italy with 36 multiplex cinemas and 362 screens. Space owns five out of the top ten highest grossing cinemas in Italy including the No.1 grossing cinema in the Italian market - Parco de Medici. The business is a leader in a fragmented cinema market. At the end of 2014, The Space Cinema was acquired by Vue Entertainment International.
About Vue International
Vue International is one of the world's leading cinema operators,
managing the most respected brands in major European markets and Taiwan,
spanning ten countries, 212 sites and 1,902 screens. The group has
leading positions in the United Kingdom, Ireland, Germany, Denmark,
Netherlands, Italy, Poland, Latvia, Lithuania and Taiwan. From its
inception in May 2003 Vue International has grown organically and
through strategic acquisition to deliver a premium out-of-home
entertainment experience by combining the best content, with the best
technology in the best environment.
Website: www.myvue.com/about-us
About Vista Group International:
Vista Group International (Vista Group) is a public company, listed on
both the New Zealand and Australian stock exchanges (NZX & ASX: VGL).
The Group provides software and additional technology solutions across
the global film industry. Cinema management software is provided by
Vista Entertainment Solutions (Vista Cinema), the core business of the
Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based
SaaS software for the Independent Cinema Market), movieXchange
(connecting the movie industry to simplify the promotion and sale of
movie tickets), Maccs (film distribution software), Numero (box office
reporting software for film distributors and cinemas), Cinema
Intelligence (business intelligence solutions), Powster (creative studio
and marketing platform for movie studios) and Flicks (moviegoer ‘go to’
portal for movie information) provide an innovative range of
complementary products across additional film industry sectors, from
production and distribution, to cinema exhibition through to the
moviegoer experience. Vista Group has offices located in New Zealand
(Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico
City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn:
www.linkedin.com/company/vista-group-limited
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006322/en/
Contact:
Media Contacts:
For Vista Group International/NZ & EUROPE
Christine
Fenby
+64 21 727 006
christine.fenby@vista.co
or
For
Vista Group International/USA
Maggie Begley/MBC
+1 310 390
0101
maggie@mbcprinc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom